CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company also has Business & Research Collaboration Agreement with SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.
Metrics to compare | GDTC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGDTCPeersSector | |
---|---|---|---|---|
P/E Ratio | −13.9x | −0.6x | −0.5x | |
PEG Ratio | −0.31 | −0.01 | 0.00 | |
Price/Book | 3.9x | 2.6x | 2.6x | |
Price / LTM Sales | 69.6x | 7.6x | 2.9x | |
Upside (Analyst Target) | 117.4% | 511.4% | 50.4% | |
Fair Value Upside | Unlock | −5.7% | 9.1% | Unlock |